Search Results

Five-Year Data From COMPARE Trial Published

July 24, 2015—Pieter C. Smits, MD, et al reported the 5-year follow-up data from the COMPARE trial of everolimus-eluting stents (EES; Xience V, Abbott Vascular) and paclitaxel-eluting stents (PES; Taxus Liberté, Boston Scientific Corporation) in an all-comers population undergoing percutaneous coronary intervention (PCI). The study is available online ahead of print in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.

SMT Supraflex Cruz DES for HBR Patients Evaluated in COMPARE RCT

October 16, 2024—Sahajanand Medical Technologies (SMT) announced results of the COMPARE 60/80 HBR trial evaluating the company’s Supraflex Cruz stent in high-bleeding-risk (HBR) patients.

Follow-Up Data Published for SIRTAX, COMPARE, and SPIRIT IV DES Trials

June 21, 2011—Follow-up data from three major drug-eluting stent (DES) trials have been published.

NIREUS Trial of Medinol's BioNIR DES Meets Primary Endpoint

May 20, 2016—The NIREUS trial, which is evaluating Medinol’s BioNIR coronary stent system and the company’s eDES elastomeric drug-eluting stent, met its noninferiority primary endpoint of angiographic in-stent late loss at 6 months.

Abbott Vascular's Xience Xpedition 48 Receives CE Mark Approval to Treat Very Long Lesions

May 21, 2013—Abbott Vascular (Santa Clara, CA) announced European CE Mark approval for the Xience Xpedition 48 everolimus-eluting coronary stent system for the treatment of very long blockages in coronary arteries.

One-Year COMPARE Results Presented at TCT

September 24, 2009—At the Transcatheter Cardiovascular Therapeutics (TCT) 2009 scientific symposium in San Francisco, the results of the COMPARE trial demonstrated improved safety and efficacy with the Xience V everolimus-eluting coronary stent system (Abbott Vascular, Santa Clara, CA) compared to the Taxus Liberté paclitaxel-eluting coronary stent system (Boston Scientific Corporation, Natick, MA), reported the conference newspaper, TCT Daily.

Large-Scale Study Compares CABG and PCI for Multivessel CAD in Medicare Patients in the United States

January 23, 2023—The Society of Thoracic Surgeons (STS) announced that a study demonstrating that for patients with multivessel coronary artery disease (CAD), those undergoing coronary artery bypass grafting (CABG) were less likely to die from their condition, less likely to need additional surgery, and less likely to experience a myocardial infarction than patients undergoing percutaneous coronary intervention (PCI).